↓ Skip to main content

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

Overview of attention for article published in Nature Medicine, February 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news
5 news outlets
blogs
1 blog
twitter
23 X users
patent
5 patents
facebook
3 Facebook pages
wikipedia
2 Wikipedia pages

Readers on

mendeley
239 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
Published in
Nature Medicine, February 2016
DOI 10.1038/nm.4038
Pubmed ID
Authors
Abstract

Although subtypes of pancreatic ductal adenocarcinoma (PDAC) have been described, this malignancy is clinically still treated as a single disease. Here we present patient-derived models representing the full spectrum of previously identified quasi-mesenchymal (QM-PDA), classical and exocrine-like PDAC subtypes, and identify two markers-HNF1A and KRT81-that enable stratification of tumors into different subtypes by using immunohistochemistry. Individuals with tumors of these subtypes showed substantial differences in overall survival, and their tumors differed in drug sensitivity, with the exocrine-like subtype being resistant to tyrosine kinase inhibitors and paclitaxel. Cytochrome P450 3A5 (CYP3A5) metabolizes these compounds in tumors of the exocrine-like subtype, and pharmacological or short hairpin RNA (shRNA)-mediated CYP3A5 inhibition sensitizes tumor cells to these drugs. Whereas hepatocyte nuclear factor 4, alpha (HNF4A) controls basal expression of CYP3A5, drug-induced CYP3A5 upregulation is mediated by the nuclear receptor NR1I2. CYP3A5 also contributes to acquired drug resistance in QM-PDA and classical PDAC, and it is highly expressed in several additional malignancies. These findings designate CYP3A5 as a predictor of therapy response and as a tumor cell-autonomous detoxification mechanism that must be overcome to prevent drug resistance.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 239 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Germany 2 <1%
United States 1 <1%
France 1 <1%
Unknown 235 98%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 52 22%
Student > Ph. D. Student 49 21%
Student > Bachelor 22 9%
Student > Master 21 9%
Student > Doctoral Student 18 8%
Other 30 13%
Unknown 47 20%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 66 28%
Medicine and Dentistry 48 20%
Agricultural and Biological Sciences 46 19%
Pharmacology, Toxicology and Pharmaceutical Science 10 4%
Chemistry 5 2%
Other 12 5%
Unknown 52 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 68. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2026.
All research outputs
#773,156
of 32,994,287 outputs
Outputs from Nature Medicine
#2,521
of 11,267 outputs
Outputs of similar age
#11,357
of 443,431 outputs
Outputs of similar age from Nature Medicine
#22
of 62 outputs
Altmetric has tracked 32,994,287 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,267 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 110.1. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,431 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.